Abrocitinib Efficacy Dose-Dependent, Similar Across AD Age G

As for adverse events, nausea was more frequent in patients aged 12-17 and aged 18-40 years than it was for those age 51 or older.

Related Keywords

New York , United States , Illinois , Chicago , Abrocitinib Cibinqo , Weill Cornell , Raj Chovatiya , Andrewf Alexis , Amgen , Pfizer , Beiersdorf , Allergan , Drug Administration , Northwestern University Feinberg School Of Medicine , Bausch Health , Revolutionizing Atopic Dermatitis , Weill Cornell Medicine , New York City , Investigator Global Assessment , Eczema Area , Severity Index , Peak Pruritus Numeric Rating Scale , Northwestern University Feinberg School , Dermatitis , Pruritus , Pruritis , Pitch , Atopic Dermatitis , Nausea , Eczema , Riga , Topical Therapy , Severity Indices , Adolescent Medicine , Europe , European , Us Food And Drug Administration , Nited States Food And Drug Administration , Fda , Health Care Quality Access Evaluation , Medical Literature , Books , Textbooks , Ournals ,